PetIQ, Inc. (PETQ) Research

PetIQ, Inc. operates as a prominent enterprise in the pet health and wellness sector, with a market presence across the United States and internationally. Its operations are strategically divided into two primary segments: Products and Services. Within its Products division, the company provides a comprehensive range of veterinary prescription medications. This includes crucial treatments for issues like flea and tick control, heartworm prevention, arthritis, thyroid disorders, diabetes management, pain relief, various antibiotics, and other specialized pharmaceuticals. PetIQ is unique in that it both develops and manufactures its own line of exclusive, value-branded products, while also serving as a distributor for numerous established third-party branded medications. Furthermore, it supplies over-the-counter (OTC) medications and related supplies, with a strong emphasis on flea and tick control and behavior management solutions. These OTC offerings are available in diverse formats, such as topical spot-on applications, chewable and oral tablets, and collars. Beyond medications, the company also features health and wellness products, including specialized dental treats and a variety of nutritional supplements for concerns like hip and joint health, general vitamins, and improvements to skin and coat. This extensive product portfolio is marketed under a wide array of brand names, including PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles. The Services segment delivers an extensive suite of veterinary care options. PetIQ manages approximately 2,900 community clinics and wellness centers, frequently hosted within pet retail locations across 42 states. These centers provide essential services such as diagnostic testing, comprehensive vaccination programs, dispensing of prescription medications, microchipping, and routine wellness examinations. With an impressive reach, PetIQ leverages approximately 60,000 distribution points, ensuring its products and services are readily available through diverse channels, including veterinary practices, traditional retail stores, and online e-commerce platforms. Established in 2010, PetIQ, Inc. is headquartered in Eagle, Idaho.

Market snapshot

Symbol
PETQ
Price
$30.98
Day change
-0.03%
Market cap
$919.2M
P/E ratio
423.56x
52-week range
15.09-31.06
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Analyst price target
$31.00

Peer companies

  • Albireo Pharma, Inc. (ALBO)
  • Atrion Corporation (ATRI)
  • BioDelivery Sciences International, Inc. (BDSI)
  • Crescent Biopharma, Inc. (CBIO)
  • Avid Bioservices, Inc. (CDMO)
  • Cardiovascular Systems, Inc. (CSII)
  • Gracell Biotechnologies Inc. (GRCL)
  • Harpoon Therapeutics, Inc. (HARP)

Recent insider activity

  • Glasman Zvi — A-Award (21268 shares) on 2024-10-24
  • Glasman Zvi — D-Return (21268 shares) on 2024-10-25
  • Glasman Zvi — D-Return (16000 shares) on 2024-10-25
  • Glasman Zvi — D-Return (36513 shares) on 2024-10-25
  • Huff Scott — D-Return (4103 shares) on 2024-10-25

Open PetIQ, Inc. (PETQ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.